Poterepatide

Metabolic / fat loss

Appetite, glucose, weight, and metabolic regulation

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Incretin / metabolic peptide or small molecule
Primary mechanism: Incretin/amylin/glucagon-axis receptor modulation
Primary market use: Metabolic / fat loss

Pharmacology

Molecular weight (Da): 5199.94
Oral bioavailability: Route-dependent / verify
Half-life: ~1–7 days (half-life-extended peptide class estimate)
Route tags: SubQ; Injectable; route-dependent
Evidence level: MCE product listing / research chemical signal
Clinical status: Research chemical/reference listing
Value-for-money score: 8 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Stackability

Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.

Notes

Poterepatide (HDM1005) is a long-acting GLP-1R/GIPR peptide dual agonist. Poterepatide exhibits potent activity on both GLP-1 and GIP receptors. Poterepatide can be used for the study of obesity and type 2 diabetes.

Sources

https://www.medchemexpress.com/poterepatide.html